U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Her2-receptor negative breast cancer

MedGen UID:
1684659
•Concept ID:
C4733095
•
Neoplastic Process
Synonym: HER2-negative breast cancer
 
Monarch Initiative: MONDO:0000618

Professional guidelines

PubMed

Current approaches to the management of Her2-negative metastatic breast cancer.
Gogineni K, DeMichele A
Breast Cancer Res 2012 Apr 10;14(2):205. doi: 10.1186/bcr3064. PMID: 22429313Free PMC Article
HER2-positive breast cancer: current and future treatment strategies.
Engel RH, Kaklamani VG
Drugs 2007;67(9):1329-41. doi: 10.2165/00003495-200767090-00006. PMID: 17547474
The curability of breast cancer and the treatment of advanced disease.
Guarneri V, Conte PF
Eur J Nucl Med Mol Imaging 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24 doi: 10.1007/s00259-004-1538-5. PMID: 15107948

Recent clinical studies

Etiology

Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer.
Chapdelaine AG, Sun G
Biomolecules 2023 Aug 1;13(8) doi: 10.3390/biom13081207. PMID: 37627272Free PMC Article
LIPG endothelial lipase and breast cancer risk by subtypes.
Gago-Dominguez M, Redondo CM, Calaza M, Matabuena M, Bermudez MA, Perez-Fernandez R, Torres-Español M, Carracedo Á, Castelao JE
Sci Rep 2021 May 17;11(1):10436. doi: 10.1038/s41598-021-89669-4. PMID: 34001944Free PMC Article
Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, Boffetta P, Weiss M
Ann Oncol 2015 Dec;26(12):2398-407. Epub 2015 Oct 26 doi: 10.1093/annonc/mdv379. PMID: 26504151Free PMC Article
Current approaches to the management of Her2-negative metastatic breast cancer.
Gogineni K, DeMichele A
Breast Cancer Res 2012 Apr 10;14(2):205. doi: 10.1186/bcr3064. PMID: 22429313Free PMC Article
HER2-positive breast cancer: current and future treatment strategies.
Engel RH, Kaklamani VG
Drugs 2007;67(9):1329-41. doi: 10.2165/00003495-200767090-00006. PMID: 17547474

Diagnosis

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat 2022 Sep;195(2):127-139. Epub 2022 May 11 doi: 10.1007/s10549-022-06602-7. PMID: 35545724Free PMC Article
Associations between neighborhood disinvestment and breast cancer outcomes within a populous state registry.
Plascak JJ, Rundle AG, Xu X, Mooney SJ, Schootman M, Lu B, Roy J, Stroup AM, Llanos AAM
Cancer 2022 Jan 1;128(1):131-138. Epub 2021 Sep 8 doi: 10.1002/cncr.33900. PMID: 34495547Free PMC Article
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG
J Cancer Res Clin Oncol 2020 Mar;146(3):605-619. Epub 2020 Feb 8 doi: 10.1007/s00432-020-03144-7. PMID: 32036454Free PMC Article
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA
J Natl Cancer Inst 2014 Apr 28;106(5) doi: 10.1093/jnci/dju055. PMID: 24777111Free PMC Article
HER2-positive breast cancer: current and future treatment strategies.
Engel RH, Kaklamani VG
Drugs 2007;67(9):1329-41. doi: 10.2165/00003495-200767090-00006. PMID: 17547474

Therapy

Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer.
Chatterjee P, Karn R, Isaac AE, Ray S
Clin Transl Oncol 2023 Nov;25(11):3057-3072. Epub 2023 Apr 20 doi: 10.1007/s12094-023-03191-9. PMID: 37079210
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat 2022 Sep;195(2):127-139. Epub 2022 May 11 doi: 10.1007/s10549-022-06602-7. PMID: 35545724Free PMC Article
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Stravodimou A, Voutsadakis IA
Anticancer Res 2020 Sep;40(9):4829-4841. doi: 10.21873/anticanres.14486. PMID: 32878771
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG
J Cancer Res Clin Oncol 2020 Mar;146(3):605-619. Epub 2020 Feb 8 doi: 10.1007/s00432-020-03144-7. PMID: 32036454Free PMC Article
Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, Boffetta P, Weiss M
Ann Oncol 2015 Dec;26(12):2398-407. Epub 2015 Oct 26 doi: 10.1093/annonc/mdv379. PMID: 26504151Free PMC Article

Prognosis

Associations between neighborhood disinvestment and breast cancer outcomes within a populous state registry.
Plascak JJ, Rundle AG, Xu X, Mooney SJ, Schootman M, Lu B, Roy J, Stroup AM, Llanos AAM
Cancer 2022 Jan 1;128(1):131-138. Epub 2021 Sep 8 doi: 10.1002/cncr.33900. PMID: 34495547Free PMC Article
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG
J Cancer Res Clin Oncol 2020 Mar;146(3):605-619. Epub 2020 Feb 8 doi: 10.1007/s00432-020-03144-7. PMID: 32036454Free PMC Article
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES, Nielsen D, Hogdall E, Balslev E
Acta Oncol 2018 Jan;57(1):74-82. Epub 2017 Nov 23 doi: 10.1080/0284186X.2017.1400180. PMID: 29168430
Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, Boffetta P, Weiss M
Ann Oncol 2015 Dec;26(12):2398-407. Epub 2015 Oct 26 doi: 10.1093/annonc/mdv379. PMID: 26504151Free PMC Article
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA
J Natl Cancer Inst 2014 Apr 28;106(5) doi: 10.1093/jnci/dju055. PMID: 24777111Free PMC Article

Clinical prediction guides

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J
Breast Cancer Res Treat 2022 Sep;195(2):127-139. Epub 2022 May 11 doi: 10.1007/s10549-022-06602-7. PMID: 35545724Free PMC Article
Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression.
Rosso C, Voutsadakis IA
Clin Breast Cancer 2022 Jun;22(4):391-397. Epub 2022 Feb 26 doi: 10.1016/j.clbc.2022.02.008. PMID: 35337735
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified.
MacNeil IA, Burns DJ, Rich BE, Soltani SM, Kharbush S, Osterhaus NG, Sullivan BF, Hawkins DM, Pietruska JR, Laing LG
J Cancer Res Clin Oncol 2020 Mar;146(3):605-619. Epub 2020 Feb 8 doi: 10.1007/s00432-020-03144-7. PMID: 32036454Free PMC Article
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES, Nielsen D, Hogdall E, Balslev E
Acta Oncol 2018 Jan;57(1):74-82. Epub 2017 Nov 23 doi: 10.1080/0284186X.2017.1400180. PMID: 29168430
HER2-positive breast cancer: current and future treatment strategies.
Engel RH, Kaklamani VG
Drugs 2007;67(9):1329-41. doi: 10.2165/00003495-200767090-00006. PMID: 17547474

Recent systematic reviews

Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ
J Natl Cancer Inst 2018 Jun 1;110(6):568-580. doi: 10.1093/jnci/djx273. PMID: 29315431
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Stovgaard ES, Nielsen D, Hogdall E, Balslev E
Acta Oncol 2018 Jan;57(1):74-82. Epub 2017 Nov 23 doi: 10.1080/0284186X.2017.1400180. PMID: 29168430
Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, Boffetta P, Weiss M
Ann Oncol 2015 Dec;26(12):2398-407. Epub 2015 Oct 26 doi: 10.1093/annonc/mdv379. PMID: 26504151Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...